Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

Summary

Ascletis announced that ASC37, a once-monthly subcutaneous triple peptide agonist, demonstrated 88% greater relative body weight reduction compared to tirzepatide in a diet-induced obese mouse model. The company plans to submit both subcutaneous and oral formulations to the FDA.